Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
Sharad Lakhanpal, MBBS, MD, Receives India’s Highest Honor for Overseas Indians In early January, Sharad Lakhanpal, MBBS, MD, MACR, FACP, a rheumatologist at Rheumatology Associates in Dallas and past president of the ACR, was one of only three Indian-Americans to receive the 2025 Pravasi Bharatiya Samman Award (PBSA). The award is conferred every two years…
The year before my hike, I was extremely busy with various ACR workforce issues; meetings; presentations, locally, regionally and nationally; juggling medical missions and more. However, I had blocked time in my calendar over one year in advance to hike the Camino de Santiago in Spain with a long-time U.S. Army buddy. I met Pat…
“Doctor, I hate to tell you this but that shelf is definitely not made of wood,” my patient gently chided me as I knocked on a plastic piece of shelving. “I know … but you get the point,” I replied with a small laugh. It’s become a habit of mine over the past few years…
Attention to factors beyond the standard nociceptive model of painin patients with hand OA, including psychosocial considerations &other comorbidities, may impact a patient’s pain perception &pain course.
Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…